The Journal of Rheumatology最新文献

{"title":"How Should We Count the Toe Joints in the 66/68 Joint Count in Psoriatic Arthritis? Results of an International Survey.","authors":"Gabriele De Marco,Helena Marzo-Ortega,Philip S Helliwell","doi":"10.3899/jrheum.2025-0072","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0072","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"121 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease Based on Serological Profiles: Focus on Anti-Centromere and Anti-RNA Polymerase III Antibodies.","authors":"Elizabeth R Volkmann,Shervin Assassi,Christopher P Denton,Rozeta Simonovska,Steven Sambevski,Margarida Alves,Elana J Bernstein","doi":"10.3899/jrheum.2024-1063","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1063","url":null,"abstract":"OBJECTIVECompare the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) based on serological status.METHODSIn a post-hoc analysis of the SENSCIS trial (nintedanib vs placebo in SSc-ILD; NCT02597933), we analyzed the rate of decline in forced vital capacity (FVC) over 52 weeks in 3 subsets: positive for anti-centromere antibody (ACA), positive for anti-RNA polymerase III antibody (ARA), negative for ACA, ARA and anti-topoisomerase I antibody (ATA).RESULTSAmong study participants who underwent baseline serological evaluation, 32/549 (5.8%) were ACA positive, 98/528 (18.6%) were ARA positive, and 127/526 (24.1%) were negative for ACA, ARA and ATA. Among the serological subsets of interest, in the placebo arm, the adjusted rate (SE) of decline in FVC (mL/year) was -31.2 (41.5) among participants who were positive for ACA and -64.7 (35.1) among participants who were positive for ARA, numerically lower than in the overall SENSCIS trial population (-93.3 [13.5]). However, participants who were negative for ACA, ARA and ATA experienced a numerically greater rate of decline in FVC (mL/year) than the overall trial population, both in those randomized to placebo (-115.6 [35.4] vs. -93.3 [13.5], respectively) and those randomized to nintedanib (-91.8 [34.3] vs. -52.4 [13.8]).CONCLUSIONThese analyses of data from the SENSCIS trial suggest that patients with SSc-ILD who are ACA positive or ARA positive can experience progression of SSc-ILD. Patients negative for ACA, ARA and ATA had a higher rate of progression than the overall trial population and should be monitored closely.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased school absence among children with juvenile idiopathic arthritis - a national matched comparison study.","authors":"Malthe Jessen Pedersen,Christian Høst,Stefan Nygaard Hansen,Jens Klotsche,Kirsten Minden,Bent Deleuran,Bodil Hammer Bech","doi":"10.3899/jrheum.2024-1182","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1182","url":null,"abstract":"OBJECTIVEThis study compares rates of school absence (SA) of all children with juvenile idiopathic arthritis (JIA) attending public Danish schools to peers both before and after JIA diagnosis. Further, we aimed to investigate the role of socioeconomic status (SES) on the possible association.METHODSWe performed a register-based matched cohort study. We included all children attending public Danish schools between 2010 and 2019 diagnosed with JIA and compared them to school mates. Rates of differentiated and total SA both before and after JIA diagnosis were compared. In the primary study we included children diagnosed with JIA after starting school, whereas the secondary study only included children diagnosed before starting school.RESULTSWe included 716 children with JIA and 3632 matched controls in the primary study and 382 children with JIA and 1910 matched controls in the secondary. Our primary study showed higher rates of sickness SA and total SA from three years before diagnosis and the following five years among children with JIA. After diagnosis, JIA children also had significantly more legal (planned) SA. Children diagnosed with JIA before starting school (secondary study) had significantly more SA (both sickness SA and legal school SA) up to 8th grade. In both studies children of low SES both with and without JIA had highest rates of SA, although no difference in the association between JIA and SA across SES groups were found.CONCLUSIONChildren with JIA had more sickness and legal absence from school.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143841201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mortality in patients with Sjögren Disease: A Prospective Cohort Study Identifying Key Predictors.","authors":"Olga Rusinovich Lovgach,Zulema Plaza,Mónica Fernández Castro,José Rosas,Victor Martínez-Taboada,Alejandro Olivé,Raul Menor Almagro,Belen Serrano Benavente,Judit Font-Urgelles,Angel Garcia-Aparicio,Sara Manrique-Arija,Jesús Alberto Garcia-Vadillo,Ruth Lopez-Gonzalez,Javier Narvaez García,Ma Beatriz Rodriguez-Lozano,Carlos Galisteo,Juan Jorge Gonzalez-Martin,Paloma Vela-Casasempere,Cristina Bohorquez,Celia Erausquin,Ma Beatriz Paredes-Romero,Leyre Riancho-Zarrabeitia,Sheila Melchor Diaz,Jose Maria Pego-Reigosa,Sergio Heredia,Clara Moriano,Ma Angeles Blazquez Cañamero,Paula Estrada,Enrique Judez,Joaquín Belzunegui Otano,Consuelo Ramos Giráldez,Marta Domínguez Álvaro,Fernando Sánchez Alonso,José Luis Andréu Sánchez","doi":"10.3899/jrheum.2024-1033","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1033","url":null,"abstract":"OBJECTIVETo quantify the mortality risk in a large, well-characterized cohort of Sjögren's disease (SjD) patients and to identify independent predictors of mortality in this population.METHODSWe included 314 patients diagnosed with SjD according to the 2002 American-European Consensus Group criteria from a prospective, multicenter SjögrenSER-PROS cohort. Detailed data on systemic manifestations, serological markers, disease activity, and mortality was collected after 9 years of follow up. The primary outcome was overall mortality, secondary analyses aimed to identify independent predictors of mortality using Cox proportional hazards models. Standardized mortality ratios were calculated by comparing the observed deaths in the SjD cohort to the expected deaths in an age- and sex-matched general population.RESULTSThe study identified a 70% increased mortality risk in the SjD cohort compared to the general population, with a standard mortality ratio (SMR) of 1.7. Infections (35.71%), malignancies (23.8%), and cardiovascular disease (7.14%) were the most common causes of death. Multivariate analysis revealed that older age (HR 1.11 per year, 95% CI 1.05-1.17), C4 hypocomplementemia (HR 3.75, 95% CI 1.52-9.24), elevated erythrocyte sedimentation rate (HR 1.01, 95% CI 1.00-1.03), history of heart failure (HR 4.24, 95% CI 1.89-9.51), and pulmonary involvement (HR 3.31, 95% CI 1.48-7.41) were independent predictors of mortality.CONCLUSIONThis study shows a significantly increased mortality risk in SjD, with infections, malignancies, and cardiovascular disease as leading causes of death. Independent predictors of mortality include advanced age, C4 hypocomplementemia, elevated ESR, heart failure, and pulmonary involvement, underscoring the need for proactive, individualized management.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"142 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic Granulomatosis With Polyangiitis Presenting With Bilateral Renal Masses.","authors":"Nehaal Ahmed,Saad Rashid,Kenneth J Warrington,Matthew J Koster","doi":"10.3899/jrheum.2024-1177","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1177","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Reshaping of Modifiable Risk Factors as a Strategy to Prevent the Development of Rheumatoid Arthritis.","authors":"Francesco Caso,Roberto Giacomelli,Marcella Nunziato,Federica Di Maggio,Raffaele Scarpa,Piero Ruscitti,Francesco Salvatore","doi":"10.3899/jrheum.2024-0545","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0545","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and risk of infections in patients with ankylosing spondylitis receiving biologic therapies: A prospective observational study using the KOBIO registry.","authors":"Kyung Min Ko,Su-Jin Moon","doi":"10.3899/jrheum.2024-0443","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0443","url":null,"abstract":"OBJECTIVEThis study aimed to assess infection occurrence of infection and risk factors among ankylosing spondylitis (AS) patients treated with biologics in a real-world setting.METHODSThis prospective observational cohort study included AS patients from the Korean College of Rheumatology BIOlogics (KOBIO) registry who initiated or switched to biologic agent between December 2012 and July 2023. The primary outcome was the first occurrence of any infection, ranging from mild to severe, classified by organ system. The infection rate per 1,000 person-years (PY), with a 95% confidence interval were calculated using the Poisson distribution method. Cox proportional hazard regression models, adjusted for confounders, estimated hazard ratios for infection risk, considering only the first infection event.RESULTSThis analysis included 2,129 patients with a total of 7,107.67 PY of follow-up. The predominant infections observed were of the upper and lower respiratory tract (25.89/1000 PY), followed by herpes zoster (HZ) (6.13/1000 PY). Multivariate Cox regression analysis revealed significant risk factors for infection, including age, ischemic heart disease, complicated diabetes, chronic kidney disease (CKD), and peripheral arthritis. In contrast, male sex was identified as a protective factor against the development of infections.CONCLUSIONThe infection rate was 39 events/1,000 PY with respiratory tract infections being most common, followed by HZ. Significant risk factors included age, female sex, ischemic heart disease, complicated diabetes, CKD and peripheral arthritis for the occurrence of infection in patients with AS treated with biologics.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind Matters in Rheumatoid Arthritis: The Rising Burden of Anxiety and Depression.","authors":"Nadia Sweet,Heather Huang,Christie M Bartels","doi":"10.3899/jrheum.2024-1273","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1273","url":null,"abstract":"","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potentially Avoidable Emergency Department Utilization by Persons with Psoriatic Arthritis and Ankylosing Spondylitis: A Population-Based Cohort Study.","authors":"Victor Mocanu,Claire E H Barber,Patrick McLane,Kelsey Chomistek,Eileen Davidson,Meghan J Elliott,Clare Hildebrandt,Steven Katz,Katie Lin,Shanon McQuitty,Nazret Russon,Brian R Holroyd,Eddy Lang,Cheryl Barnabe","doi":"10.3899/jrheum.2024-1113","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1113","url":null,"abstract":"OBJECTIVEGreater accessibility to ambulatory services may mitigate emergency department (ED) presentations for lower acuity issues. This study examined ED utilization patterns for individuals with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) in a universal access healthcare setting.METHODSLinked population-based administrative datasets in Alberta, Canada (fiscal years 2008-2017) were assessed for yearly ED visit frequency, timing, triage acuity, most responsible diagnoses, and disposition for persons with PsA and AS.RESULTSA total of 4,984 individuals with PsA and 14,690 with AS had 53,174 and 124,037 unique ED encounters, respectively. On average, 47.6% of persons with PsA and 35.7% with AS accessed the ED annually. Low acuity encounters (triaged as less urgent or non-urgent) were common, comprising 44.2% and 50.3% of visits for PsA and AS cohorts, respectively. Infection and injury were the most common responsible diagnoses. Presentations for arthritis flares were infrequent (1.2% and 2.0% for PsA and AS cohorts, respectively) with no significant differences by sex or urbanicity. Rural patients had nearly twice the mean number of visits per year, had a higher frequency of less acute presentations, and were admitted less often in both disease cohorts. Sex differences included differential timing of presentation to EDs, and females with PsA had a lower frequency of admission relative to males.CONCLUSIONED use for less and non-urgent health concerns was frequent for persons with PsA and AS, particularly in rural settings. These data can inform tailored health service delivery including access solutions for persons residing in rural areas.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: Final results from the RA-BEYOND study.","authors":"Christopher J Edwards,Gerhard Krönke,Jérôme Avouac,Zhanguo Li,Fabrizio Conti,Alejandro Balsa,Daojun Mo,Ewa Haladyj,Peter Fischer,Masaru Tanaka,Yasushi Takita,Kohei Hagimori,Tsutomu Takeuchi","doi":"10.3899/jrheum.2024-0906","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0906","url":null,"abstract":"OBJECTIVEThis study examines the impact of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4-mg once-daily up to 96-weeks.METHODSPatients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4-mg for ≥15 months and maintained clinical disease activity index (CDAI) low disease activity (LDA) or remission (REM) were blindly randomized to continue 4-mg or taper to 2-mg. If needed, 2-mg treated patients could be rescued to 4-mg, and 4-mg treated patients could be rescued by adding or increasing conventional synthetic disease-modifying antirheumatic drugs. Efficacy and safety were assessed through 96-weeks. Non-responder imputation, considering rescued or discontinued patients as non-responders, was used for CDAI response analyses.RESULTSAt 96-weeks, most patients maintained LDA in both 2-mg and 4-mg arms, with a lower maintenance rate in 2-mg than 4-mg (NRI 59.9% and 70.2%, respectively). Patients maintained REM in 2-mg and 4-mg arms, 30.8% and 36.6% respectively. Rescue rates were 14.7% for baricitinib 4-mg and 22.5% for 2-mg. Of 112 patients who lost LDA in the 2-mg arm and rescued to 4-mg, 76.2% and 75.6% achieved LDA again at 12- and 24-weeks post-rescue.CONCLUSIONIn a randomized, blinded, phase 3 LTE study, maintenance of RA control following induction of sustained LDA/REM with baricitinib 4-mg was greater with continued 4-mg than after taper to 2-mg. Nonetheless, 76% of patients tapered to 2-mg could maintain LDA/REM or recapture with return to 4-mg if needed.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142988807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}